Literature DB >> 32894543

LncRNA CASC2 inhibits cell proliferation, metastasis and EMT through miR-18a/SOCS5 axis in cholangiocarcinoma.

L Peng1, Y-H Liu, S Nie, M Gao.   

Abstract

OBJECTIVE: Cholangiocarcinoma (CCA) is one of the tumors with high malignancy of the liver and bile system, whose development and prognosis mechanisms are still not clear. Here, a preliminary illustration was made on the expression and function of long non-coding RNA (lncRNA) CASC2 and the relevant mechanism of its function. PATIENTS AND METHODS: Expression of CASC2 in CCA tissues and cells were examined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Cell proliferation ability was detected using colony formation and Cell Counting Kit-8 (CCK-8) assays while cell invasion and migration abilities were measured using transwell and Matrigel assays. Using bioinformatic analysis, underlying downstream molecules of CASC2 were predicted and by Dual-Luciferase assay and Western blot.
RESULTS: It was found that CASC2 was expressed at a significantly lower level in CCA tissues and cell lines. The overexpression of CASC2 inhibited QBC939 cell proliferation, invasion and migration when the knockdown of CASC2 accelerated HUCCT1 cell growth and metastasis. Besides, miR-18a was identified as a direct target for CASC2, and SOCS5 as target for miR-18a. Moreover, CASC2 functioned as a sponge of miR-18a to promote the SOCS5 expression, then, slowed down the epithelial-to-mesenchymal transition (EMT) progression.
CONCLUSIONS: CASC2 was downregulated in CCA tissues and cells. It could inhibit cell proliferation, invasion, migration and EMT via sponging miR-18a/SOCS5 axis. This might provide a novel target for CCA diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32894543     DOI: 10.26355/eurrev_202008_22633

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  10 in total

Review 1.  Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma.

Authors:  Yanhua Wu; Khizar Hayat; Yufei Hu; Jianfeng Yang
Journal:  Front Cell Dev Biol       Date:  2022-04-27

2.  Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and In Vitro Experiments.

Authors:  Yuan Yao; Dechao Jiao; Zaoqu Liu; Jianjian Chen; Xueliang Zhou; Zhaonan Li; Jing Li; Xinwei Han
Journal:  Biomed Res Int       Date:  2020-12-09       Impact factor: 3.411

3.  Leonurine-Repressed miR-18a-5p/SOCS5/JAK2/STAT3 Axis Activity Disrupts CML malignancy.

Authors:  Hui-Min Liu; Chun-Ling Guo; Yao-Fang Zhang; Jian-Fang Chen; Zhi-Peng Liang; Lin-Hua Yang; Yan-Ping Ma
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

4.  The lncRNA CASC2 Modulates Hepatocellular Carcinoma Cell Sensitivity and Resistance to TRAIL Through Apoptotic and Non-Apoptotic Signaling.

Authors:  Jichun Sun; Hongbo Xu; Zhao Lei; Zhiqiang Li; Hongwei Zhu; Zhen Deng; Xiao Yu; Xiaoxin Jin; Zhi Yang
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

5.  LINC00630 promotes cholangiocarcinoma cell proliferation, migration and invasion by mediating the miR-199a/FGF7 axis.

Authors:  Baiyin Zhong; Caixin Song; Qingfang He; Zhixi Chen; Qicheng Liao; Qiusheng Xiong; Shijie Wang; Yuansheng Xiao; Xing Xie; Yuankang Xie; Xiaonong Wang; Jianhong Zhang
Journal:  J Cancer       Date:  2022-01-04       Impact factor: 4.207

6.  MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/β-Catenin Signaling Pathway.

Authors:  Chao Liu; Yanli Li; Lichao Zhang; Pei Zhang; Ning Yu; Xuefang Liu; Huaihai Lu; Haiming Du; Senlin Hou
Journal:  J Oncol       Date:  2022-04-12       Impact factor: 4.501

7.  Potential of circulating lncRNA CASC2 as a biomarker in reflecting the inflammatory cytokines, multi-organ dysfunction, disease severity, and mortality in sepsis patients.

Authors:  Rui Wang; Jinglin Zhao; Qi Wei; Hao Wang; Chao Zhao; Caihong Hu; Yu Han; Zhi Hui; Long Yang; Qingchun Dai; Cuicui Liu
Journal:  J Clin Lab Anal       Date:  2022-06-26       Impact factor: 3.124

8.  LncRNA CASC2 is involved in the development of chronic obstructive pulmonary disease via targeting miR-18a-5p/IGF1 axis.

Authors:  Panpan Liu; Huali Zhang; Haizhu Zeng; Yingxia Meng; Hongchang Gao; Meilan Zhang; Lei Zhao
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

9.  microRNA-206 Suppresses Cholangiocarcinoma Cell Growth and Invasion by Targeting Jumonji AT-Rich Interactive Domain 2.

Authors:  Chunying Xie; Zhenxing Huang; Zhaohui Huang; Xue Zhang; Siyuan Lou
Journal:  Dig Dis Sci       Date:  2021-07-08       Impact factor: 3.487

10.  lncRNA TMPO antisense RNA 1 promotes the malignancy of cholangiocarcinoma cells by regulating let-7g-5p/ high-mobility group A1 axis.

Authors:  Hongbin Chang; Yixin Yao
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.